aspartic acid has been researched along with Colonic Neoplasms in 51 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Colonic Neoplasms: Tumors or cancer of the COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| "alpha-Methylacyl-CoA racemase (AMACR), an enzyme involved in oxidation of branched chain fatty acids and cholesterol metabolites, as well as ibuprofen metabolism, is overexpressed in colorectal adenomas and cancer." | 5.12 | Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma. ( Chatterjee, N; Daugherty, SE; Fallin, MD; Hayes, RB; Huang, WY; Isaacs, WB; Platz, EA; Shugart, YY; Welch, R, 2007) |
| "Twenty-eight patients with advanced adenocarcinoma were treated with a combination of thymidine, 5-FU, and PALA." | 3.67 | Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. ( Bedikian, A; Bodey, GP; Chiuten, DF; Freireich, EJ; Valdivieso, M, 1985) |
| "Twenty-seven patients with colorectal adenocarcinoma, (12) non-small cell bronchogenic carcinoma, (11) gastric adenocarcinoma (3), and adenocarcinoma of unknown primary lesion (1) were treated with the combination of thymidine (TdR), 5-fluorouracil (FU), and N-phosphonacetyl-L-aspartic acid (PALA)." | 3.67 | Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study. ( Bedikian, A; Benvenuto, JA; Bodey, GP; Chiuten, DF; Freireich, EJ; Loo, TL; Miller, A; Valdivieso, M, 1985) |
| "In 2594 patients with complete adverse event (AE) data, the incidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88." | 2.79 | DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). ( Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA, 2014) |
| " Treatment was well tolerated; 4/27 patients experienced > or = ECOG grade 3 toxicity at full 5-FU dosage (500 mg/m2 bolus/infusion)." | 2.67 | A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer. ( Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Kerr, DJ; Oster, W; Steward, WP; Yosef, H, 1994) |
| "However, its function in colon cancer remains to be further revealed." | 1.62 | Integration of transcriptomics and metabolomics reveals anlotinib-induced cytotoxicity in colon cancer cells. ( Jia, Z; Li, A; Tian, Q; Wu, H; Xie, Y; Yang, Z; Zhang, H; Zhang, X; Zhang, Z, 2021) |
| "We assessed the risk of colon cancer among individuals with and without HFE gene mutations." | 1.32 | Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. ( Galanko, J; Keku, T; Lawrence, LB; Martin, CF; Rohlfs, EM; Sandler, RS; Shaheen, NJ; Silverman, LM, 2003) |
| "In two ulcerative colitis patients, a mutation was found in the Ki-ras gene (Gly --> Asp 12 and Gly --> Val 12), and in one patient, a mutation in exon 5 of the p53 gene." | 1.30 | Detection of Ki-ras mutations by PCR and differential hybridization and of p53 mutations by SSCP analysis in endoscopically obtained lavage solution from patients with long-standing ulcerative colitis. ( Heinzlmann, M; Lang, SM; Loeschke, K; Stratakis, DF; Teschauer, W, 1997) |
| "Modulation of the therapeutic efficacy of cisplatin (CDDP) and 5-fluoro-2'-deoxyuridine (FdUrd) alone and in combination with N-phosphonacetyl-L-aspartate (PALA) was evaluated in mice bearing colon carcinoma (C-26) using a weekly intravenous (i." | 1.29 | Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26. ( Cao, S; Durrani, FA; Mayhew, EG; Peters, GJ; Rustum, YM; Van Laar, JA, 1995) |
| "On the other hand, the pattern in colon cancer was more similar to the colon mucosal layer than the full-thickness layer of normal colon tissue." | 1.29 | Increased aspartate and glutamate levels in both gastric and colon cancer tissues. ( Kita, Y; Komi, N; Miyake, H; Nishi, M; Okada, A; Takehara, H; Yoshida, K, 1993) |
| "In contrast, colorectal cancers with codon 12 aspartic acid substitutions accounted for most of the distant hematogenous deposits (P < 0." | 1.29 | Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. ( Christensen, S; Finkelstein, SD; Sayegh, R; Swalsky, PA, 1993) |
| " Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures." | 1.27 | Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer. ( Camacho, FJ; Engstrom, PF; Green, MD; Greenwald, ES; Kaplan, BH; Muggia, FM; Wernz, JC, 1987) |
| "One of the responding patients with colon cancer and two with breast cancer had failed to respond to prior therapy with 5-FU; one of the responding patients with breast cancer had previously received an inadequate trial of a similar regimen." | 1.26 | Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. ( Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR, 1982) |
| "Both normal and colonic cancer cells, when cultured in the presence of these agents, cease to increase their cell numbers." | 1.26 | Antiproliferative agents and differential survival between normal and cancer cells. ( Kwong, LK; Tsuboi, KK, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (43.14) | 18.7374 |
| 1990's | 14 (27.45) | 18.2507 |
| 2000's | 6 (11.76) | 29.6817 |
| 2010's | 5 (9.80) | 24.3611 |
| 2020's | 4 (7.84) | 2.80 |
| Authors | Studies |
|---|---|
| Altinok, O | 1 |
| Poggio, JL | 1 |
| Stein, DE | 1 |
| Bowne, WB | 1 |
| Shieh, AC | 1 |
| Snyder, NW | 1 |
| Orynbayeva, Z | 1 |
| Deng, L | 1 |
| Yao, P | 1 |
| Li, L | 1 |
| Ji, F | 1 |
| Zhao, S | 1 |
| Xu, C | 1 |
| Lan, X | 1 |
| Jiang, P | 1 |
| Jia, Z | 1 |
| Zhang, Z | 1 |
| Tian, Q | 1 |
| Wu, H | 1 |
| Xie, Y | 1 |
| Li, A | 1 |
| Zhang, H | 1 |
| Yang, Z | 1 |
| Zhang, X | 1 |
| Naz, S | 1 |
| Leiker, AJ | 1 |
| Choudhuri, R | 1 |
| Preston, O | 1 |
| Sowers, AL | 1 |
| Gohain, S | 1 |
| Gamson, J | 1 |
| Mathias, A | 1 |
| Van Waes, C | 1 |
| Cook, JA | 1 |
| Mitchell, JB | 1 |
| Gao, S | 1 |
| Hu, J | 1 |
| Wu, X | 1 |
| Liang, Z | 1 |
| Dihal, AA | 1 |
| Boot, A | 1 |
| van Roon, EH | 1 |
| Schrumpf, M | 1 |
| Fariña-Sarasqueta, A | 1 |
| Fiocco, M | 1 |
| Zeestraten, EC | 1 |
| Kuppen, PJ | 1 |
| Morreau, H | 1 |
| van Wezel, T | 1 |
| Boer, JM | 1 |
| Gonsalves, WI | 1 |
| Mahoney, MR | 1 |
| Sargent, DJ | 2 |
| Nelson, GD | 1 |
| Alberts, SR | 2 |
| Sinicrope, FA | 2 |
| Goldberg, RM | 2 |
| Limburg, PJ | 1 |
| Thibodeau, SN | 1 |
| Grothey, A | 1 |
| Hubbard, JM | 1 |
| Chan, E | 1 |
| Nair, S | 1 |
| Berenberg, JL | 2 |
| McWilliams, RR | 1 |
| Lee, AM | 1 |
| Shi, Q | 1 |
| Pavey, E | 1 |
| Diasio, RB | 1 |
| Graboń, W | 1 |
| Otto-Ślusarczyk, D | 1 |
| Chrzanowska, A | 1 |
| Mielczarek-Puta, M | 1 |
| Joniec-Maciejak, I | 1 |
| Słabik, K | 1 |
| Barańczyk-Kuźma, A | 1 |
| Shaheen, NJ | 1 |
| Silverman, LM | 1 |
| Keku, T | 1 |
| Lawrence, LB | 1 |
| Rohlfs, EM | 1 |
| Martin, CF | 1 |
| Galanko, J | 1 |
| Sandler, RS | 1 |
| Al-Fageeh, M | 1 |
| Li, Q | 1 |
| Dashwood, WM | 1 |
| Myzak, MC | 1 |
| Dashwood, RH | 1 |
| Kumagai, M | 1 |
| Imai, Y | 1 |
| Nakamura, T | 1 |
| Yamasaki, Y | 1 |
| Sekino, M | 1 |
| Ueno, S | 1 |
| Hanaoka, K | 1 |
| Kikuchi, K | 1 |
| Nagano, T | 1 |
| Kaneko, E | 1 |
| Shimokado, K | 1 |
| Kataoka, K | 2 |
| Daugherty, SE | 1 |
| Platz, EA | 1 |
| Shugart, YY | 1 |
| Fallin, MD | 1 |
| Isaacs, WB | 1 |
| Chatterjee, N | 1 |
| Welch, R | 1 |
| Huang, WY | 1 |
| Hayes, RB | 1 |
| Presant, CA | 2 |
| Ardalan, B | 3 |
| Multhauf, P | 1 |
| Chan, C | 1 |
| Staples, R | 1 |
| Green, L | 1 |
| Browning, S | 1 |
| Carr, BI | 1 |
| Chang, FF | 1 |
| Thayer, W | 1 |
| Bedikian, AY | 1 |
| Jamin, D | 1 |
| Jayaram, HN | 1 |
| O'Connell, MJ | 3 |
| Rubin, J | 3 |
| Schutt, AJ | 3 |
| Moertel, CG | 4 |
| Kvols, LK | 2 |
| Hahn, RG | 1 |
| Gertz, MA | 1 |
| Yang, LY | 1 |
| Drewinko, B | 1 |
| Erlichman, C | 3 |
| Donehower, RC | 1 |
| Speyer, JL | 1 |
| Klecker, R | 1 |
| Chabner, BA | 2 |
| Weiss, GR | 1 |
| Ervin, TJ | 1 |
| Meshad, MW | 1 |
| Kufe, DW | 1 |
| Karle, JM | 1 |
| Anderson, LW | 1 |
| Cysyk, RL | 1 |
| Van Laar, JA | 2 |
| Mayhew, EG | 1 |
| Cao, S | 1 |
| Durrani, FA | 2 |
| Peters, GJ | 1 |
| Rustum, YM | 2 |
| Seitz, JF | 1 |
| Piedbois, P | 1 |
| Lévy, E | 1 |
| Le Bourgeois, JP | 1 |
| Buyse, M | 1 |
| Jodrell, DI | 1 |
| Oster, W | 1 |
| Kerr, DJ | 1 |
| Canney, PA | 1 |
| Yosef, H | 1 |
| Steward, WP | 1 |
| Kaye, SB | 1 |
| Cassidy, J | 1 |
| Kamm, VJ | 1 |
| Rietjens, IM | 1 |
| Vervoort, J | 1 |
| Heerschap, A | 1 |
| Rosenbusch, G | 1 |
| Hofs, HP | 1 |
| Wagener, DJ | 1 |
| Okada, A | 1 |
| Takehara, H | 1 |
| Yoshida, K | 1 |
| Nishi, M | 1 |
| Miyake, H | 1 |
| Kita, Y | 1 |
| Komi, N | 1 |
| Wadler, S | 1 |
| Mao, X | 1 |
| Bajaj, R | 1 |
| Hallam, S | 1 |
| Schwartz, EL | 1 |
| Finkelstein, SD | 2 |
| Sayegh, R | 2 |
| Bakker, A | 1 |
| Swalsky, P | 1 |
| Christensen, S | 1 |
| Swalsky, PA | 1 |
| Cleaveland, ES | 1 |
| Zaharevitz, DW | 1 |
| Kelley, JA | 1 |
| Paull, K | 1 |
| Cooney, DA | 1 |
| Ford, H | 1 |
| Lang, SM | 1 |
| Heinzlmann, M | 1 |
| Stratakis, DF | 1 |
| Teschauer, W | 1 |
| Loeschke, K | 1 |
| Paranavitana, CM | 1 |
| Kim, JS | 1 |
| Heath, TD | 1 |
| Mizumura, Y | 1 |
| Matsumura, Y | 1 |
| Hamaguchi, T | 1 |
| Nishiyama, N | 1 |
| Kawaguchi, T | 1 |
| Hrushesky, WJ | 1 |
| Moriyasu, F | 1 |
| Kakizoe, T | 1 |
| Osieka, R | 1 |
| Houchens, DP | 1 |
| Goldin, A | 1 |
| Johnson, RK | 1 |
| Strong, JM | 1 |
| Wiernik, PH | 1 |
| McAvoy, LM | 1 |
| Cohen, MH | 1 |
| Levine, AS | 1 |
| Hubbard, SM | 1 |
| Tsuboi, KK | 2 |
| Kwong, LK | 2 |
| Edmunds, NH | 1 |
| Bruckner, HW | 1 |
| Motwani, BT | 1 |
| Buroker, TR | 1 |
| Fleming, TR | 1 |
| Everson, LK | 1 |
| Cullinan, SA | 1 |
| Krook, JE | 1 |
| Mailliard, JA | 1 |
| Marschke, RF | 1 |
| Klaassen, DJ | 1 |
| Laurie, JA | 1 |
| Floersheim, GL | 1 |
| Chiodetti, N | 1 |
| Bieri, A | 1 |
| Singh, G | 1 |
| Silberman, H | 1 |
| Muggia, FM | 1 |
| Camacho, FJ | 1 |
| Kaplan, BH | 1 |
| Green, MD | 1 |
| Greenwald, ES | 1 |
| Wernz, JC | 1 |
| Engstrom, PF | 1 |
| Chan, TC | 1 |
| Young, B | 1 |
| King, ME | 1 |
| Taetle, R | 1 |
| Howell, SB | 1 |
| Chiuten, DF | 2 |
| Valdivieso, M | 2 |
| Bedikian, A | 2 |
| Bodey, GP | 2 |
| Freireich, EJ | 2 |
| Miller, A | 1 |
| Loo, TL | 1 |
| Benvenuto, JA | 1 |
| Ohnuma, T | 1 |
| Holland, JF | 1 |
| Freeman, A | 1 |
| Sinks, LF | 1 |
4 reviews available for aspartic acid and Colonic Neoplasms
| Article | Year |
|---|---|
Regional and systemic chemotherapy for advanced colorectal cancer. A review.
Topics: Antineoplastic Agents; Aspartic Acid; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; D | 1983 |
[Chemotherapy in cancers of the colon].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chemotherapy, | 1993 |
[Chemotherapy of metastasizing cancers of the colon and rectum].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neopla | 1993 |
Chemotherapy of advanced cancer of the colon and rectum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Fluorouracil; Huma | 1991 |
6 trials available for aspartic acid and Colonic Neoplasms
| Article | Year |
|---|---|
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
Topics: Adenoma; Aged; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspartic Acid; Case-Control Studies | 2007 |
Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma.
Topics: Adult; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trials | 1983 |
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neop | 1994 |
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Drug Evaluat | 1985 |
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1988 |
41 other studies available for aspartic acid and Colonic Neoplasms
| Article | Year |
|---|---|
Malate-aspartate shuttle promotes l-lactate oxidation in mitochondria.
Topics: Aspartic Acid; Colonic Neoplasms; HCT116 Cells; Homeostasis; Humans; Lactic Acid; Malates; Mitochond | 2020 |
p53-mediated control of aspartate-asparagine homeostasis dictates LKB1 activity and modulates cell survival.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Asparagine; Aspartate-Ammonia Ligase; Aspartic Acid; | 2020 |
Integration of transcriptomics and metabolomics reveals anlotinib-induced cytotoxicity in colon cancer cells.
Topics: Aspartic Acid; Cell Cycle Proteins; Chondroitin Sulfate Proteoglycans; Chromatography, Liquid; Chrom | 2021 |
Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
Topics: Animals; Aspartic Acid; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Co | 2021 |
PMA treated THP-1-derived-IL-6 promotes EMT of SW48 through STAT3/ERK-dependent activation of Wnt/β-catenin signaling pathway.
Topics: 6-Aminonicotinamide; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; beta Catenin; Ce | 2018 |
The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors.
Topics: Aged; Aspartic Acid; Cell Line, Tumor; Colonic Neoplasms; DNA Methylation; DNA Mutational Analysis; | 2013 |
Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.
Topics: Adult; Aged; Aspartic Acid; Clinical Trials, Phase III as Topic; Colonic Neoplasms; DNA Mismatch Rep | 2014 |
Lactate Formation in Primary and Metastatic Colon Cancer Cells at Hypoxia and Normoxia.
Topics: Aspartate Aminotransferases; Aspartic Acid; Cell Count; Cell Hypoxia; Cell Line, Tumor; Colonic Neop | 2016 |
Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspartic Acid; Case-Control Studies; Col | 2003 |
Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.
Topics: Amino Acid Substitution; Animals; Aspartic Acid; beta Catenin; Binding Sites; Colonic Neoplasms; Cyt | 2004 |
Iron hydroxide nanoparticles coated with poly(ethylene glycol)-poly(aspartic acid) block copolymer as novel magnetic resonance contrast agents for in vivo cancer imaging.
Topics: Animals; Aspartic Acid; Coated Materials, Biocompatible; Colonic Neoplasms; Contrast Media; Female; | 2007 |
Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
Topics: Adult; Aged; Aspartic Acid; Carcinoma; Colonic Neoplasms; Drug Administration Schedule; Drug Eruptio | 1983 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Ataxia; Colonic Neoplasm | 1984 |
A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carmusti | 1984 |
A method to measure carcinoembryonic antigen neosynthesis by cultured colon carcinoma cells.
Topics: Acetylglucosamine; Aspartic Acid; Carcinoembryonic Antigen; Carcinoma; Cell Line; Chromatography, Af | 1980 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Th | 1982 |
Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Colonic Neoplasms; Drug Evaluation; Humans; Melanoma | 1980 |
Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colonic Neoplasms | 1995 |
Effect of modulators on 5-fluorouracil metabolite patterns in murine colon carcinoma determined by in vitro 19F nuclear magnetic resonance spectroscopy.
Topics: Animals; Aspartic Acid; Colonic Neoplasms; Female; Fluorine; Fluorouracil; Interferon-alpha; Leucovo | 1994 |
Increased aspartate and glutamate levels in both gastric and colon cancer tissues.
Topics: Aspartic Acid; Colonic Neoplasms; Gastric Mucosa; Glutamates; Glutamic Acid; Humans; Intestinal Muco | 1993 |
N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Aspartic Acid; Base | 1993 |
Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Cytidine Triphosphate; Dose-Respon | 1993 |
Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis.
Topics: Adenocarcinoma; Aspartic Acid; Biomarkers, Tumor; Codon; Colonic Neoplasms; DNA, Neoplasm; Exons; Fo | 1993 |
Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type.
Topics: Adenine; Adenocarcinoma; Aspartic Acid; Biology; Codon; Colonic Neoplasms; Gene Frequency; Genes, ra | 1993 |
Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Topics: Antineoplastic Agents; Aspartic Acid; Biphenyl Compounds; Breast Neoplasms; Carbolines; Carcinoma, N | 1996 |
Detection of Ki-ras mutations by PCR and differential hybridization and of p53 mutations by SSCP analysis in endoscopically obtained lavage solution from patients with long-standing ulcerative colitis.
Topics: Aspartic Acid; Biopsy; Case-Control Studies; Cell Transformation, Neoplastic; Codon; Colitis, Ulcera | 1997 |
Non-radioactive detection of K-ras mutations by nested allele specific PCR and oligonucleotide hybridization.
Topics: Alanine; Amino Acid Substitution; Animals; Aspartic Acid; Breast Neoplasms; Codon; Colonic Neoplasms | 1998 |
In vitro cytotoxic effect of N-(phosphonacetyl)-L-aspartic acid in liposome against C-26 murine colon carcinoma.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Carriers; Liposomes; Mice; Pa | 2000 |
Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Cell Survival; Cisplatin; Colonic Neoplasms; Drug Carriers | 2001 |
Chemotherapy of human colon cancer xenografts in athymic nude mice.
Topics: Acridines; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcinoma | 1977 |
Phase I trial of N-(phosphonacetyl)-L-aspartate.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Colonic Neoplasms; Diarrhea; Drug Eruptions; Drug Evaluation | 1979 |
Antiproliferative agents and differential survival between normal and cancer cells.
Topics: Adenocarcinoma; Aspartic Acid; Cell Cycle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasm | 1978 |
Selective inhibition of pyrimidine biosynthesis and effect on proliferative growth of colonic cancer cells.
Topics: Animals; Aspartic Acid; Cell Division; Cells, Cultured; Colonic Neoplasms; DNA, Neoplasm; Humans; Ki | 1977 |
Differential radioprotection of bone marrow and tumour cells by zinc aspartate.
Topics: Adenocarcinoma; Animals; Aspartic Acid; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Colonic Ne | 1988 |
Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Central Nervous System D | 1987 |
Modulation of the activity of PALA by dipyridamole.
Topics: Animals; Aspartic Acid; Biological Transport; Cell Line; Colonic Neoplasms; Dipyridamole; Drug Inter | 1985 |
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic | 1985 |
Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinom | 1985 |
Biochemical and pharmacological studies with asparaginase in man.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asparaginase; Asparagine; Aspartic Acid; Child; Colo | 1970 |